Department of Surgery, University of Michigan, Ann Arbor.
Michigan Opioid Prescribing Engagement Network, Ann Arbor.
JAMA Surg. 2019 Jan 1;154(1):e184234. doi: 10.1001/jamasurg.2018.4234. Epub 2019 Jan 16.
There is growing evidence that opioids are overprescribed following surgery. Improving prescribing requires understanding factors associated with opioid consumption.
To describe opioid prescribing and consumption for a variety of surgical procedures and determine factors associated with opioid consumption after surgery.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective, population-based analysis of the quantity of opioids prescribed and patient-reported opioid consumption across 33 health systems in Michigan, using a sample of adults 18 years and older undergoing surgery. Patients were included if they were prescribed an opioid after surgery. Surgical procedures took place between January 1, 2017, and September 30, 2017, and were included if they were performed in at least 25 patients.
Opioid prescription size in the initial postoperative prescription.
Patient-reported opioid consumption in oral morphine equivalents. Linear regression analysis was used to calculate risk-adjusted opioid consumption with robust standard errors.
In this study, 2392 patients (mean age, 55 years; 1353 women [57%]) underwent 1 of 12 surgical procedures. Overall, the quantity of opioid prescribed was significantly higher than patient-reported opioid consumption (median, 30 pills; IQR, 27-45 pills of hydrocodone/acetaminophen, 5/325 mg, vs 9 pills; IQR, 1-25 pills; P < .001). The quantity of opioid prescribed had the strongest association with patient-reported opioid consumption, with patients using 0.53 more pills (95% CI, 0.40-0.65; P < .001) for every additional pill prescribed. Patient-reported pain in the week after surgery was also significantly associated with consumption but not as strongly as prescription size. Compared with patients reporting no pain, patients used a mean (SD) 9 (1) more pills if they reported moderate pain and 16 (2) more pills if they reported severe pain (P < .001). Other significant risk factors included history of tobacco use, American Society of Anesthesiologists class, age, procedure type, and inpatient surgery status. After adjusting for these risk factors, patients in the lowest quintile of opioid prescribing had significantly lower mean (SD) opioid consumption compared with those in the highest quintile (5 [2] pills vs 37 [3] pills; P < .001).
The quantity of opioid prescribed is associated with higher patient-reported opioid consumption. Using patient-reported opioid consumption to develop better prescribing practices is an important step in combating the opioid epidemic.
越来越多的证据表明,手术后开阿片类药物的处方过多。改进处方需要了解与术后阿片类药物消费相关的因素。
描述各种手术的阿片类药物处方和使用情况,并确定与手术后阿片类药物使用相关的因素。
设计、环境和参与者:这是一项在密歇根州 33 个卫生系统中进行的回顾性、基于人群的分析,使用了接受手术的 18 岁及以上成年人的样本,研究了手术后开具的阿片类药物数量和患者报告的阿片类药物使用情况。如果患者在手术后开了阿片类药物处方,则将其纳入研究。手术于 2017 年 1 月 1 日至 9 月 30 日进行,如果至少有 25 名患者进行了手术,则将其纳入研究。
初始术后处方中阿片类药物的处方量。
患者报告的以口服吗啡当量表示的阿片类药物使用情况。使用稳健标准误差的线性回归分析来计算风险调整后的阿片类药物使用量。
本研究中,2392 名患者(平均年龄 55 岁;女性 1353 名[57%])接受了 12 种手术中的 1 种。总体而言,开具的阿片类药物数量明显高于患者报告的阿片类药物使用量(中位数,30 片;IQR,27-45 片氢可酮/对乙酰氨基酚,5/325mg,与 9 片;IQR,1-25 片;P < .001)。开具的阿片类药物数量与患者报告的阿片类药物使用量相关性最强,每增加 1 片处方,患者就会多使用 0.53 片(95%CI,0.40-0.65;P < .001)。术后一周患者报告的疼痛也与使用量显著相关,但不如处方量那么强。与报告无疼痛的患者相比,报告中度疼痛的患者平均(SD)多使用 9 (1)片,报告重度疼痛的患者多使用 16 (2)片(P < .001)。其他显著的风险因素包括吸烟史、美国麻醉医师协会分级、年龄、手术类型和住院手术状态。在调整这些风险因素后,阿片类药物处方量最低的五分位数患者的平均(SD)阿片类药物使用量明显低于处方量最高的五分位数患者(5[2]片比 37[3]片;P < .001)。
开具的阿片类药物数量与患者报告的阿片类药物使用量较高有关。使用患者报告的阿片类药物使用情况来制定更好的处方实践是对抗阿片类药物流行的重要一步。